Tylosin is a coccidiostatic food additive used in veterinary medicine. It has a broad spectrum of activity against gram positives and a limited range of gram negatives but has been shown to be active against Campylobacter, E. coli, and spirochaetes. It is extremely active against Mycoplasma species isolated from both mammalian and avian hosts [[1]. It is found naturally as a fermentation product of Streptomyces fradiae.

Tylosin is used in veterinary medicine to treat bacterial infections in a wide range of species and has a high margin of safety. It has also been used as a growth promoter in some species, and as a treatment for colitis in companion animals.

Like other macrolides, tylosin has a bacteriostatic effect on susceptible organisms, caused by inhibition of protein synthesis through binding to the 50S subunit of the bacterial ribosome.

Therapeutic use

Tylosin has been used to treat a variety of different diseases. In general, tylosin is licensed for the treatment of infections caused by organisms susceptible to the drug, but it has also been used as a treatment of colitis in small animals, as a growth promotant in food producing animals. Examples of bacterial infections that could potentially be treated with tylosin include respiratory infections, metritis, and acute mastitis in cattle; mastitis in sheep and goats; enteritis, pneumonia, erysipelas, and infectious arthritis in swine; and soft tissue infections in small animals. While tylosin may be one appropriate therapeutic choice in theory for the conditions listed above.


Oral administration can result in diarrhoea and gastrointestinal disturbance. This is particularly true of horses, such that it can be fatal. Tylosin also has a foul taste that is difficult to disguise. The injectable formulations of tylosin can cause pain, inflammation, and itchiness around the injection site.





Medicinal Chemistry

CAS number: 1401-69-0   EINECS:

Molecular Formula: C46H77NO17

Average mass:
Monoisotopic mass:

Systematic name: [(2R,3R,4E,6E,9R,11R,12S,13S,14R) -12- {[3,6-dideoxy-4-O-(2,6-dideoxy-3-C-methyl-α-L-ribo-hexopyranosyl) -3- (dimethylamino)-β-D-glucopyranosyl]oxy}-2-ethyl-14-hydroxy-5, 9,13-trimethyl-8, 16-dioxo-11-(2-oxoethyl)oxacyclohexadeca-4,6-dien-3-yl]methyl 6-deoxy-2,3-di-O-methyl-β-D-allopyranoside

Std. InChI:

Melting Point:



1. Antimicrobial Therapy in Veterinary Medicine, by Steeve Giguere, P. M. Dowling, ISBN 978-0-8138-0656-3


     Hit Counter


Send mail to stefano.biondi@innovativesolution.it with questions or comments about this web site.
Copyright 2010 Innovative Solution di Biondi Stefano